Edesa Biotech Stock Performance
| EDSA Stock | USD 1.51 0.03 1.95% |
The firm shows a Beta (market volatility) of 0.82, which means possible diversification benefits within a given portfolio. As returns on the market increase, Edesa Biotech's returns are expected to increase less than the market. However, during the bear market, the loss of holding Edesa Biotech is expected to be smaller as well. At this point, Edesa Biotech has a negative expected return of -0.74%. Please make sure to confirm Edesa Biotech's skewness, day typical price, and the relationship between the maximum drawdown and daily balance of power , to decide if Edesa Biotech performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Edesa Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in February 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Last Split Factor 1:7 | Dividend Date 2019-06-10 | Last Split Date 2023-10-11 |
1 | Is Edesa Biotech Inc. still worth holding after the dip - Weekly Stock Summary Smart Money Movement Alerts - newser.com | 10/24/2025 |
2 | Favourable Signals For Edesa Biotech Numerous Insiders Acquired Stock | 10/28/2025 |
3 | EDSA EB05 Reduces Risk of Death 25 percent in Phase 3 ARDS Trial | 11/05/2025 |
4 | Is Edesa Biotech Inc. stock affected by interest rate hikes - Trade Signal Summary Daily Momentum Trading Reports - newser.com | 11/13/2025 |
5 | Will Edesa Biotech Inc. stock deliver better than expected guidance - newser.com | 11/17/2025 |
6 | Acquisition by Nijhawan Pardeep of 8766 shares of Edesa Biotech subject to Rule 16b-3 | 12/01/2025 |
7 | EDSA Gearing Up to Initiate Phase 2 Vitiligo Trial in Mid-2026 | 12/15/2025 |
8 | Acquisition by Nijhawan Pardeep of 10444 shares of Edesa Biotech subject to Rule 16b-3 | 01/05/2026 |
Edesa Biotech Relative Risk vs. Return Landscape
If you would invest 254.00 in Edesa Biotech on October 11, 2025 and sell it today you would lose (103.00) from holding Edesa Biotech or give up 40.55% of portfolio value over 90 days. Edesa Biotech is currently does not generate positive expected returns and assumes 4.6915% risk (volatility on return distribution) over the 90 days horizon. In different words, 42% of stocks are less volatile than Edesa, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Edesa Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Edesa Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Edesa Biotech, and traders can use it to determine the average amount a Edesa Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1569
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | EDSA |
Based on monthly moving average Edesa Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Edesa Biotech by adding Edesa Biotech to a well-diversified portfolio.
Edesa Biotech Fundamentals Growth
Edesa Stock prices reflect investors' perceptions of the future prospects and financial health of Edesa Biotech, and Edesa Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Edesa Stock performance.
| Return On Equity | -1.0 | ||||
| Return On Asset | -0.57 | ||||
| Current Valuation | 11.4 M | ||||
| Shares Outstanding | 8.33 M | ||||
| Price To Earning | (3.96) X | ||||
| Price To Book | 3.89 X | ||||
| Price To Sales | 120,478 X | ||||
| Gross Profit | 311.2 K | ||||
| EBITDA | (7.07 M) | ||||
| Net Income | (7.19 M) | ||||
| Cash And Equivalents | 12.81 M | ||||
| Cash Per Share | 0.83 X | ||||
| Total Debt | 1.21 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 2.68 X | ||||
| Book Value Per Share | 0.45 X | ||||
| Cash Flow From Operations | (7.32 M) | ||||
| Earnings Per Share | (1.27) X | ||||
| Market Capitalization | 12.83 M | ||||
| Total Asset | 13.53 M | ||||
| Retained Earnings | (65.91 M) | ||||
| Working Capital | 10.43 M | ||||
| Current Asset | 6.92 M | ||||
| Current Liabilities | 581.49 K | ||||
About Edesa Biotech Performance
By analyzing Edesa Biotech's fundamental ratios, stakeholders can gain valuable insights into Edesa Biotech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Edesa Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Edesa Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 45.16 | 47.42 | |
| Return On Tangible Assets | (0.67) | (0.70) | |
| Return On Capital Employed | (0.50) | (0.53) | |
| Return On Assets | (0.52) | (0.55) | |
| Return On Equity | (1.26) | (1.32) |
Things to note about Edesa Biotech performance evaluation
Checking the ongoing alerts about Edesa Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Edesa Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Edesa Biotech generated a negative expected return over the last 90 days | |
| Edesa Biotech may become a speculative penny stock | |
| Edesa Biotech has high historical volatility and very poor performance | |
| Edesa Biotech has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (7.19 M) with profit before overhead, payroll, taxes, and interest of 311.2 K. | |
| Edesa Biotech currently holds about 12.81 M in cash with (7.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.83. | |
| Roughly 17.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Nijhawan Pardeep of 10444 shares of Edesa Biotech subject to Rule 16b-3 |
- Analyzing Edesa Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Edesa Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Edesa Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Edesa Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Edesa Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Edesa Biotech's stock. These opinions can provide insight into Edesa Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Edesa Stock analysis
When running Edesa Biotech's price analysis, check to measure Edesa Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edesa Biotech is operating at the current time. Most of Edesa Biotech's value examination focuses on studying past and present price action to predict the probability of Edesa Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edesa Biotech's price. Additionally, you may evaluate how the addition of Edesa Biotech to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |